MA41287A - Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement - Google Patents
Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellementInfo
- Publication number
- MA41287A MA41287A MA041287A MA41287A MA41287A MA 41287 A MA41287 A MA 41287A MA 041287 A MA041287 A MA 041287A MA 41287 A MA41287 A MA 41287A MA 41287 A MA41287 A MA 41287A
- Authority
- MA
- Morocco
- Prior art keywords
- restricted
- hla molecules
- against cancer
- absolute quantification
- process allowing
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000011002 quantification Methods 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 238000011230 antibody-based therapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 238000011161 development Methods 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 229940023041 peptide vaccine Drugs 0.000 abstract 1
- 238000012546 transfer Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
La présente invention se rapporte à un procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement, à savoir la détermination du nombre de copies d'un ou de plusieurs peptides tel que présenté par cellule. La présente invention peut non seulement être utilisée pour le développement des traitements par anticorps ou des vaccins peptidiques mais est également très précieuse pour une immunosurveillance dont la composition moléculaire a été définie, et utile dans les procédés d'identification de nouveaux antigènes peptidiques pour des stratégies immunothérapeutiques, telles que des vaccins respectifs, des thérapies à base d'anticorps ou des approches de transfert adoptif de lymphocytes t dans la lutte contre le cancer et/ou les maladies auto-immunes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097994P | 2014-12-30 | 2014-12-30 | |
| GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| PCT/EP2015/079873 WO2016107740A1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41287A true MA41287A (fr) | 2017-11-08 |
| MA41287B1 MA41287B1 (fr) | 2021-07-29 |
Family
ID=52471641
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41287A MA41287B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
| MA40137A MA40137B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40137A MA40137B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10545154B2 (fr) |
| EP (1) | EP3241026B1 (fr) |
| JP (1) | JP6735741B2 (fr) |
| KR (1) | KR102336968B1 (fr) |
| CN (1) | CN107003322B (fr) |
| AU (1) | AU2015373584B2 (fr) |
| BR (1) | BR112017008212B1 (fr) |
| CA (1) | CA2972306C (fr) |
| CL (1) | CL2017001071A1 (fr) |
| CO (1) | CO2017004543A2 (fr) |
| CR (1) | CR20170297A (fr) |
| CY (1) | CY1124223T1 (fr) |
| DK (1) | DK3241026T3 (fr) |
| EA (1) | EA036328B1 (fr) |
| ES (1) | ES2871035T3 (fr) |
| GB (1) | GB201423361D0 (fr) |
| HR (1) | HRP20210811T1 (fr) |
| HU (1) | HUE054455T2 (fr) |
| IL (1) | IL250982B (fr) |
| LT (1) | LT3241026T (fr) |
| MA (2) | MA41287B1 (fr) |
| MD (1) | MD3241026T2 (fr) |
| MX (1) | MX383806B (fr) |
| MY (1) | MY190199A (fr) |
| PE (1) | PE20171136A1 (fr) |
| PH (1) | PH12017500483A1 (fr) |
| PL (1) | PL3241026T3 (fr) |
| PT (1) | PT3241026T (fr) |
| RS (1) | RS61914B1 (fr) |
| SG (2) | SG11201703841VA (fr) |
| SI (1) | SI3241026T1 (fr) |
| TW (1) | TWI632370B (fr) |
| UA (1) | UA122774C2 (fr) |
| WO (1) | WO2016107740A1 (fr) |
| ZA (1) | ZA201701646B (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| TWI755158B (zh) | 2015-03-17 | 2022-02-11 | 德商英麥提克生物技術股份有限公司 | 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合 |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| LT3652215T (lt) | 2017-07-14 | 2021-05-25 | Immatics Biotechnologies Gmbh | Pagerinta dvejopo savitumo polipeptido molekulė |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| US11464800B2 (en) * | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| KR102731127B1 (ko) | 2018-09-05 | 2024-11-18 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| PH12021553042A1 (en) | 2019-06-06 | 2023-09-11 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| US20210041454A1 (en) | 2019-08-09 | 2021-02-11 | Immatics US, Inc. | Methods for peptide mass spectrometry fragmentation prediction |
| US12480958B2 (en) | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| BR112022016909A2 (pt) | 2020-02-24 | 2022-12-06 | Immatics Us Inc | Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| MX2022014636A (es) | 2020-05-19 | 2023-02-23 | Amgen Inc | Construcciones de unión a mageb2. |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| MX2023012899A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Polipeptidos de union a antigeno bma031 mejorados. |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| EP4113120A1 (fr) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Procédé de caractérisation des caractéristiques de liaison entre un peptide d'intérêt et des molécules du cmh |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| MX2024001179A (es) | 2021-07-27 | 2024-02-27 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a ct45. |
| EP4392441A1 (fr) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| UY39967A (es) | 2021-10-06 | 2023-05-15 | Immatics Biotechnologies Gmbh | Indicaciones para los aglutinantes anti-PRAME |
| EP4448108A1 (fr) | 2021-11-08 | 2024-10-23 | Immatics Biotechnologies GmbH | Traitement combiné de thérapie cellulaire adoptive et compositions associées |
| JP2025515604A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法 |
| EP4514829A1 (fr) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4519418A1 (fr) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Procédés d'amélioration de l'efficacité d'un lymphocyte t |
| WO2025008513A1 (fr) | 2023-07-05 | 2025-01-09 | Immatics Biotechnologies Gmbh | Procédé d'identification de protéines de liaison au cmh et de peptides interagissant dans un échantillon |
| WO2025021968A1 (fr) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Protéines de liaison à l'antigène dirigées contre mageb2 |
| WO2025021979A1 (fr) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Nouveaux récepteurs de lymphocytes t ciblant un antigène associé au mélanome (mage) b2 et thérapie immunitaire l'utilisant |
| WO2025040598A2 (fr) | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides affichés par cmh destinés à être utilisés en immunothérapie contre différents types de cancer |
| WO2025096649A1 (fr) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
| WO2025125536A1 (fr) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Prédiction du nombre absolu de copies de peptides présentés par le cmh par mesure quantitative relative |
| WO2025125535A1 (fr) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Immunopeptidomique différentielle à l'échelle d'une population |
| WO2025233432A1 (fr) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Utilisation et dosage d'une protéine de liaison à l'antigène comprenant un tcr spécifique d'un peptide restreint par hla-a*02 |
| WO2025233431A1 (fr) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Protéines hétéromères comprenant trois hétéromérisations améliorant la substitution, production, combinaisons et applications associées |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732378B2 (en) | 2001-09-14 | 2010-06-08 | Electrophoretics Limited | Mass labels |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
| WO2004042401A1 (fr) | 2002-11-08 | 2004-05-21 | Hiroshi Takahashi | Procede d'examen de cellules cancereuses et reactif associe |
| JP2007519910A (ja) | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 腫瘍関連ペプチドの同定および定量方法 |
| JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2697655A2 (fr) | 2011-04-15 | 2014-02-19 | Micromass UK Limited | Procédé et appareil pour l'analyse d'échantillons biologiques |
| US9869684B2 (en) | 2011-06-24 | 2018-01-16 | Definitek, Inc. | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening |
| US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| EP4219543A1 (fr) * | 2017-11-06 | 2023-08-02 | Immatics Biotechnologies GmbH | Nouveaux récepteurs de lymphocytes t modifiés et thérapie immunitaire les utilisant |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en active Active
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh not_active Expired - Fee Related
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
- 2015-12-15 MX MX2017008722A patent/MX383806B/es unknown
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/fr not_active Ceased
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh not_active IP Right Cessation
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active Active
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/fr active Active
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 CA CA2972306A patent/CA2972306C/fr active Active
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
-
2017
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
-
2024
- 2024-04-18 US US18/638,970 patent/US20240280583A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41287A (fr) | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement | |
| Naghavian et al. | Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma | |
| Tanoue et al. | A defined commensal consortium elicits CD8 T cells and anti-cancer immunity | |
| Tcyganov et al. | Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy | |
| Li et al. | SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer | |
| Harshman et al. | Characterization of multiple myeloma vesicles by label‐free relative quantitation | |
| Brennick et al. | An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejection | |
| Vauchy et al. | CD20 alternative splicing isoform generates immunogenic CD 4 helper T epitopes | |
| HRP20201671T1 (hr) | Postupci predviđanja korisnosti neoantigena za imunoterapiju | |
| MA40929A (fr) | Procédé de production d'anticorps à affinité élevée | |
| Durgeau et al. | Human preprocalcitonin self-antigen generates TAP-dependent and-independent epitopes triggering optimised T-cell responses toward immune-escaped tumours | |
| Rose et al. | Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I: C)-stimulated macrophages | |
| Ninkovic et al. | Shaping the treatment paradigm based on the current understanding of the pathobiology of multiple myeloma: an overview | |
| Marijt et al. | Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement | |
| MX369413B (es) | Peptido. | |
| Kim et al. | Immune checkpoint blockade augments changes within oncolytic virus-induced cancer MHC-I peptidome, creating novel antitumor CD8 T cell reactivities | |
| Vormehr et al. | Personalized neo-epitope vaccines for cancer treatment | |
| Dar et al. | c-Myc uses Cul4b to preserve genome integrity and promote antiviral CD8+ T cell immunity | |
| Martínez-Cortés et al. | Tumor antigen-unbiased variable epitope library contains mimotopes with antitumor effect in a mouse model of breast cancer | |
| Tang et al. | Thalidomide mitigates Crohn's disease colitis by modulating gut microbiota, metabolites, and regulatory T cell immunity | |
| Lema et al. | Cross-decoration of dendritic cells by non-inherited maternal antigen-containing extracellular vesicles: Potential mechanism for PD-L1-based tolerance in cord blood and organ transplantation | |
| Shraibman et al. | HLA peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy | |
| Talpin et al. | Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer | |
| Esprit et al. | An mRNA-based workflow validating neo-epitope presentation through HLA-I/peptide affinity purification | |
| Whittaker | Understanding the Rules of Antigen Presentation in Melanoma |